CSIMarket
 


Anixa Biosciences Inc   (ANIX)
Other Ticker:  
 

Anixa Biosciences Inc 's Leverage Ratio

ANIX's quarterly Leverage Ratio and Total Liabilities, Equity growth




ANIX Leverage Ratio (Oct 31 2022)
IV. Quarter
(Jul 31 2022)
III. Quarter
(Apr 30 2022)
II. Quarter
(Jan 31 2022)
I. Quarter
(Oct 31 2021)
IV. Quarter
Y / Y Equity Change -18.89 % -13.8 % -15.24 % 154.16 % 320.68 %
Y / Y Total Liabilities Change 66.44 % 47.42 % -27.03 % 32.32 % 28.86 %
Leverage Ratio MRQ 0.05 0.03 0.02 0.04 0.02
Overall Ranking # 88 # 61 # 43 # 111 # 79
Seq. Equity Change -8.76 % -1.59 % -5.52 % -4.39 % -3.03 %
Seq. Total Liabilities Change 58.35 % 37.7 % -50.9 % 55.47 % 40.25 %



Leverage Ratio forth quarter 2022 Comment
Due to net new borrowings of 58.35%, Leverage Ratio detoriated to 0.05, below company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 28 other companies have achieved lower Leverage Ratio than Anixa Biosciences Inc . While total ranking remained unchanged compare to previous quarter at no. .

Explain Leverage Ratio?
Who are ANIX Customers?
Leverage Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 29
Healthcare Sector # 44
Overall Market # 88


Leverage Ratio Statistics
High Average Low
87.48 3.3 0.02
(Jul 31 2014)   (Jul 31 2021)




Financial Statements
Anixa Biosciences Inc 's Equity $ 28 Millions Visit ANIX's Balance sheet
Anixa Biosciences Inc 's Total Liabilities $ 1 Millions Visit ANIX's Balance sheet
Source of ANIX's Sales Visit ANIX's Sales by Geography


Cumulative Anixa Biosciences Inc 's Leverage Ratio

ANIX's Leverage Ratio for the trailling 12 Months

ANIX Leverage Ratio

(Oct 31 2022)
IV. Quarter
(Jul 31 2022)
III. Quarter
(Apr 30 2022)
II. Quarter
(Jan 31 2022)
I. Quarter
(Oct 31 2021)
IV. Quarter
Y / Y Equity TTM Growth -18.89 % -13.8 % -15.24 % 154.16 % 320.68 %
Y / Y Total Liabilities TTM Growth 66.44 % 47.42 % -27.03 % 32.32 % 28.86 %
Leverage Ratio TTM 0.03 0.03 0.02 0.03 0.03
Total Ranking TTM # 106 # 107 # 103 # 149 # 98
Seq. Equity TTM Growth -8.76 % -1.59 % -5.52 % -4.39 % -3.03 %
Seq. Total Liabilities TTM Growth 58.35 % 37.7 % -50.9 % 55.47 % 40.25 %


TTM Leverage Ratio Comment
On the trailing twelve months basis Despite of the net new borrowings of 58.35% Anixa Biosciences Inc managed to unchange Leverage Ratio in IV. Quarter to 0.03, below Anixa Biosciences Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 43 other companies have achieved lower Leverage Ratio than Anixa Biosciences Inc . While Leverage Ratio total ranking has improved so far to 0, from total ranking in previous quarter at 106.

Explain Leverage Ratio?
Who are ANIX Customers?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 44
Healthcare Sector # 58
Within the Market # 106


TTM Leverage Ratio Statistics
High Average Low
2.14 0.4 0.05
(Oct 31 2016)   (Apr 30 2022)




Companies with similar Leverage Ratio in the quarter ending Oct 31 2022, within Major Pharmaceutical Preparations Industry Leverage RatioOct 31 2022 MRQ Total LiabilitiesOct 31 2022 MRQ Equity
Sensei Biotherapeutics Inc   0.13 $ 14.817  Millions$ 113.986  Millions
Galecto Inc   0.13 $ 9.298  Millions$ 72.727  Millions
Relmada Therapeutics Inc   0.12 $ 20.777  Millions$ 166.345  Millions
Vanda Pharmaceuticals Inc   0.12 $ 63.633  Millions$ 515.657  Millions
Tff Pharmaceuticals Inc   0.12 $ 2.205  Millions$ 18.023  Millions
Acurx Pharmaceuticals inc   0.12 $ 1.182  Millions$ 9.763  Millions
Larimar Therapeutics Inc   0.12 $ 14.353  Millions$ 118.662  Millions
Reviva Pharmaceuticals Holdings Inc   0.12 $ 2.453  Millions$ 20.360  Millions
Chemomab Therapeutics Ltd   0.12 $ 5.351  Millions$ 44.624  Millions
Pliant Therapeutics Inc   0.12 $ 40.187  Millions$ 336.994  Millions
Fulcrum Therapeutics Inc   0.12 $ 26.391  Millions$ 221.414  Millions
Moleculin Biotech Inc   0.12 $ 6.955  Millions$ 58.417  Millions
Shattuck Labs Inc   0.12 $ 23.525  Millions$ 199.418  Millions
Synlogic Inc   0.12 $ 11.602  Millions$ 100.428  Millions
Adicet Bio Inc   0.12 $ 36.645  Millions$ 317.658  Millions
Ideaya Biosciences Inc   0.11 $ 42.138  Millions$ 368.769  Millions
Longboard Pharmaceuticals Inc   0.11 $ 8.153  Millions$ 72.037  Millions
Milestone Pharmaceuticals Inc   0.11 $ 8.614  Millions$ 77.155  Millions
Agios Pharmaceuticals Inc   0.11 $ 116.725  Millions$ 1,050.170  Millions
Biomea Fusion Inc   0.11 $ 14.415  Millions$ 130.635  Millions
Oncternal Therapeutics Inc   0.11 $ 7.504  Millions$ 68.544  Millions
Citius Pharmaceuticals Inc   0.11 $ 11.173  Millions$ 103.426  Millions
Oric Pharmaceuticals Inc   0.11 $ 23.178  Millions$ 214.819  Millions
Alx Oncology Holdings Inc  0.11 $ 30.726  Millions$ 286.963  Millions
Immunic Inc   0.11 $ 11.514  Millions$ 108.810  Millions
Akero Therapeutics Inc   0.10 $ 35.900  Millions$ 343.508  Millions
Context Therapeutics Inc   0.10 $ 3.933  Millions$ 38.072  Millions
Cormedix Inc   0.10 $ 5.765  Millions$ 56.312  Millions
Indaptus Therapeutics Inc   0.10 $ 2.782  Millions$ 27.567  Millions
Hillstream Biopharma Inc   0.10 $ 0.717  Millions$ 7.116  Millions

Date modified: 2023-01-05T10:18:53+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SMFI's Profile

Stock Price

SMFI's Financials

Business Description

Fundamentals

Charts & Quotes

SMFI's News

Suppliers

SMFI's Competitors

Customers & Markets

Economic Indicators

SMFI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071